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The advancement of information technology in recent 
years has generated a huge amount of datasets in all 
areas of scientific research. This has led to new 
opportunities to harness the ‘Big Data’ to improve our 
understanding of diseases - from investigating disease 
mechanisms to monitoring treatment responses. 
The Big Data approach is a data-driven and often 
hypothesis-free, way of studying a disease. It generally 
involves multiple research centres pooling together 
resources and setting up consortia to generate large-scale 
datasets. Standardised protocols are used to acquire data 
that traverse molecular, genetic, clinical and imaging 
domains, hence allowing integration of clinical and 
biological data for large scale cohort study. Such 
standardised approach also enables pooled data from 
different centres to be studied and compared, which 
greatly increases statistical power. The datasets are 
usually made accessible to the wider scientific 
community, further enhancing scientific collaboration 
and transparency. It also reduces redundant/duplicative 
efforts and is potentially a more cost effective way to 
conduct large-scale scientific studies (Editorial, 2014). 
Such approach has been particularly productive in the 
field of genomics. Genome Wide Association Studies 
(GWAS) involving thousands of patients have 
successfully identified susceptibility genetic loci for 
Parkinson’s Disease (PD) (Simon-Sanchez et al., 2009). 
In its simplest form, GWAS analysis, as representative 
of the basic analytical approach to processing Big Data, 
aims to identify genetic variants such as single-
nucleotide polymorphism that distinguish a population 
with a particular trait or disease from a control 
population. For diseases with more complex genotypic 
and phenotypic components such as PD, network 
analysis has increasingly been used to identify a group or 
network of interacting genes which may be implicated in 
disease pathogenesis (Leiserson et al., 2013). Such 
network analysis has also been applied in imaging 
studies to investigate networks of anatomically dispersed 
brain regions and their roles in diseases. A number of 
statistical approaches including linear regression, logistic 
regression, principle component analysis and latent class 
analysis have been employed to analyse these large 
datasets (Wang et al., 2014) but it is beyond the scope of 
this editorial to explain them in detail. 
Parkinson’s Progression Markers Initiative (PPMI), 
sponsored by the Michael J Fox Foundation for 
Parkinson’s Research, is a multi-centre collaborative 
observational study that collects clinical, behavioural, 
imaging, genetic and biological sampling from cohorts 
of significant interest - and these include de novo PD 
patients and participants at high risk of developing PD. It 
provides a standardised and longitudinal PD database 
and biorepository which are open to the wider scientific 
community. It has the stated aim of finding one or more 
biological markers for the disease as the critical next step 
towards developing new treatments (PPMI, 2014). 
Several high-profile brain imaging collaborative 
studies including Human Brain Project, Brain Activity 
Map and BRAIN initiative (Brain Research through 
Advancing Innovative Neurotechnologies Initiative) have 
been set up to better understand brain functions, either by 
creating a large-scale computer simulation of the brain or 
by establishing a functional connectome of the brain, with 
the hope that this will eventually lead to a cure for 
neurodegenerative disorders such as Alzheimer’s and 
Parkinson’s disease (Kandel et al., 2013). 
These large-scale studies can be costly and there are 
disagreements within the scientific community on how 
best to run them and whether they will achieve the 
stated aims (OMECCHBP, 2014). There are also 
statistical and computing challenges when processing 
such large volume of data. Many statistical models do 
not account for possible interdependence of the 
multiple parameters being sampled and this could lead 
to reduction of the degree of freedom and violation of 
some statistical principles. The statistical models 
themselves may also introduce a degree of bias and 
false discovery (Wang et al., 2014).  
Critics have also argued that the Big Data approach 
can identify correlations between different disease 
parameters but it does not necessarily establish true 
causal associations and they struggle to see how this will 
lead to finding a cure for the diseases in question. 
Proponents of the Big Data approach counter-argue that 
such ‘signals’ are crucial in inspiring more hypothesis-
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driven studies to further evaluate the correlations and 
improve our understanding of diseases (Husain, 2014). 
It is important to realise the benefits and limitations 
of the Big Data approach in studying a disease. It allows 
a large-scale, unbiased study of data obtained from 
molecular to individual levels. It does not supplant 
independent research conducted by individual research 
groups, which are crucial in generating ideas and 
hypotheses to complement the Big Data approach. The 
correlations or ‘signals’ obtained from the Big Data 
approach require further targeted studies to elucidate the 
underlying molecular mechanisms. 
Apart from its role in helping us to understand diseases 
at the population level, the Big Data approach can also be 
applied, albeit on a smaller scale, on an individual basis to 
monitor disease fluctuations or treatment responses 
especially in a disease with marked between- and within-
individual variability like PD. As the disease progresses, 
most PD patients will develop motor complications such 
as wearing-OFF, ‘ON-OFF’ fluctuations, dyskinesias and 
gait freezing. The emergence of these symptoms reflects 
fluctuations in synaptic dopamine and other 
neurochemical levels in the brain. PD treatments, 
especially dopamine replacement therapy, will need to be 
titrated on an individual basis and, ideally, tailored to 
specific symptoms at a particular time. 
The traditional methods of monitoring fluctuating PD 
symptoms based on patients’ or carers’ history, or PD 
diaries, are laborious and can be misleading as they rely 
on patients or their carers to accurately identify various 
‘OFF‘ or ‘ON’ symptoms, e.g., tremor versus 
dyskinesias. Clinic reviews provide only a snapshot of 
the patients’ symptoms and signs in a rather artificial and 
potentially stressful, setting. There can also be 
discordance between treatment responses rated by 
patients and their physicians (Davidson et al., 2012). 
Mobile or wearable devices worn on patients’ limbs 
or body are being developed to detect ‘ON’/‘OFF’ limb 
movements, balance deficits and gait disorders in PD 
patients using specific algorithms. They aim to allow the 
treating neurologists to monitor an individual’s PD 
symptoms continuously, remotely and objectively in 
real-life situations (Maetzler et al., 2013). Recently, 
Michael J Fox Foundation announced a collaboration 
with Intel to use wearable devices to monitor symptoms 
of PD patients. The devices record more than 300 
observations per second from each patient and a Big 
Data platform has been developed by Intel to analyse the 
volume of data that will be generated (MJFFPR, 2014). 
Similarly, Parkinson’s UK has also teamed up with 
Global Kinetics Corporation to provide a wearable 
device Parkinson’s KinetiGraph in a 12-month pilot 
project (EPDA, 2014). 
This type of data with small sample size (individual 
patient) and high dimensionality (multiple measurements 
or parameters) is more susceptible to noise accumulation 
and spurious correlations (Fan et al., 2014). One way to 
get round this problem is by pre-processing the raw data 
to extract a more manageable secondary dataset of 
interest (Wang et al., 2014). While the statistical 
methods and algorithms involved might seem complex 
to most clinicians, the outcome generated is generally 
user-friendly (e.g., indicating dyskinesias versus 
bradykinesia) so most clinicians should not require 
extensive training or IT knowledge to avail themselves 
of the devices. The more commonly used wearable 
devices, which are applied on the patients’ forearm or 
wrist, are good at detecting motor fluctuations involving 
the monitored limb but are less sensitive at detecting gait 
disturbances or postural instability. To detect these 
abnormalities, one would often need to apply monitoring 
devices on patients’ trunk or leg and they may be 
perceived as more intrusive by patients. 
Further validation studies are required to verify the 
accuracy of these devices in detecting or interpreting 
various clinical parameters before they can be used in 
routine clinical practice. We also need more evidence 
to show that such interventions can lead to better 
patient outcome. 
Conclusion  
The Big Data approach has the potential to 
revolutionise medical research by improving 
standardisation and collaboration across different 
centres, enhancing statistical power and efficiency of 
medical studies. It also needs to be complemented by 
more specific hypotheses-driven studies. On an 
individual level, such approach can help to better 
monitor symptoms and lead to personalised treatments 
for PD patients. 
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